Tipo de documento: | Patente |
Inventor(es): | Ana Marisa Chudzinski-Tavassi; Cleyson Valença Reis; Paulo Lee Ho; Celso Romero Ramos |
Depositante: | Biolab Sanus Farmacêutica Ltda ; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) |
Data do depósito: | 24 de agosto de 2005 |
Registro INPI: | |
IPC: | C07K 14/435 |
This invention refers to the process for obtaining the recombinant prothrombin activating protease (rLopap) in monomeric form, the recombinant prothrombin activating protease (rLopap), as well as its amino acid sequence. In addition to that, this invention also refers to the use of this protease for depleting the blood fibrinogen, and serve as diagnosis kit for dysprothrombinemias. This invention describes the obtainence in recombinant form and the characterization of a prothrombin activator protease of 21 kDa, named rLopap (Lonomia obliqua prothrombin activator protease), with serineproteases characteristics however it shows sequence of conserved amino acids as in a lipocalin family. The protein presents pro-coagulating activity, depleting blood fibrinogen and prolonging the coagulation time of human blood/ plasma. The obtainence of rLopap in its recombinant form and showing adequate activity for allowing clinical Pharmacology essays is presented in this invention.
Processo FAPESP: | 02/05874-4 - Efeito de proteases (fibrinolíticos e ativadores de fatores da coagulação) obtidos de venenos animais sobre células endotelias (HUVECs) e plaquetas. |
Beneficiário: | Márcio Fritzen |
Pesquisador responsável: | Ana Marisa Chudzinski-Tavassi |
Instituição: | Secretaria da Saúde (São Paulo - Estado). Instituto Butantan |
Modalidade de apoio: | Bolsas no Brasil - Doutorado |